Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 6/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 10/20 | 0.39 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.39 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | BRAF | P15056 | 4/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108870 | 0.88 | LOXL2 (0.39) | RAF1LOXL2KDRTNNI3KMAP2K7 | |
| SCHEMBL5114217 | 0.88 | LOXL2 (0.39) | RAF1LOXL2KDRTNNI3KMAP2K7 | |
| SCHEMBL5108423 | 0.84 | KDR (0.45) | LOXL2KDRTNNI3KMAPK14BRAF | |
| SCHEMBL5108477 | 0.82 | MCHR1 (0.37) | RAF1LOXL2KDRTNNI3KMAP2K7 | |
| SCHEMBL5113699 | 0.82 | FGFR1 (0.44) | LOXL2KDR | |
| SCHEMBL6038797 | 0.80 | LOXL2 (0.37) | LOXL2KDRTNNI3KMAP2K7 | |
| SCHEMBL5108081 | 0.80 | MAP2K7 (0.38) | LOXL2KDRTNNI3KMAP2K7MAPK14 | |
| SCHEMBL6038812 | 0.78 | KDR (0.55) | KDRTNNI3K | |
| SCHEMBL5107848 | 0.78 | MAP2K7 (0.39) | LOXL2KDRTNNI3KMAP2K7BRAF | |
| SCHEMBL6038791 | 0.77 | MAP2K7 (0.39) | LOXL2KDRTNNI3KMAP2K7BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | RAF1 1150/4885LOXL2 4089/4885KDR 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.